VBI Vaccines (NASDAQ:VBIV) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

According to Zacks, “VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus vaccine. Its second platform is a thermostable technology that enables the development of vaccines and biologics. VBI Vaccines Inc., formerly known as SciVac Therapeutics, Inc., is headquartered in Cambridge, MA. “

Other equities analysts have also recently issued research reports about the stock. Canaccord Genuity initiated coverage on shares of VBI Vaccines in a research note on Wednesday, November 1st. They set a “buy” rating and a $10.00 target price on the stock. BidaskClub cut shares of VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Finally, BMO Capital Markets initiated coverage on shares of VBI Vaccines in a research note on Wednesday, November 15th. They set an “outperform” rating and a $11.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. VBI Vaccines currently has a consensus rating of “Hold” and an average price target of $8.75.

VBI Vaccines (NASDAQ:VBIV) traded up $0.01 during trading on Friday, reaching $4.44. 96,352 shares of the company’s stock traded hands, compared to its average volume of 209,765. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.97 and a current ratio of 1.03. VBI Vaccines has a 52-week low of $3.04 and a 52-week high of $6.60.

In other news, CEO Jeff Baxter bought 15,000 shares of the firm’s stock in a transaction on Tuesday, November 28th. The stock was bought at an average cost of $4.75 per share, for a total transaction of $71,250.00. Following the completion of the acquisition, the chief executive officer now directly owns 135,255 shares in the company, valued at approximately $642,461.25. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Life Sciences Maste Perceptive bought 3,100,000 shares of the firm’s stock in a transaction on Thursday, October 26th. The stock was purchased at an average price of $3.05 per share, with a total value of $9,455,000.00. The disclosure for this purchase can be found here. Insiders bought a total of 4,080,738 shares of company stock worth $12,480,151 in the last ninety days. Corporate insiders own 54.50% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. acquired a new position in shares of VBI Vaccines in the third quarter worth about $1,329,000. Bank of New York Mellon Corp acquired a new position in shares of VBI Vaccines in the second quarter worth about $193,000. TIAA CREF Investment Management LLC acquired a new position in shares of VBI Vaccines in the second quarter worth about $262,000. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of VBI Vaccines by 2.7% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 1,415,650 shares of the biopharmaceutical company’s stock worth $5,450,000 after buying an additional 37,660 shares during the period. Finally, Northern Trust Corp acquired a new position in shares of VBI Vaccines in the second quarter worth about $883,000. Institutional investors own 20.93% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2018/01/06/vbi-vaccines-vbiv-cut-to-hold-at-zacks-investment-research.html.

About VBI Vaccines

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Get a free copy of the Zacks research report on VBI Vaccines (VBIV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.